Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY3873862

Oligonucleotide (Antisense oligonucleotide) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer
1 Registered trials

What is LY3873862?

LY3873862 is an antisense oligonucleotide that acts on SOD1 RNA to lower production of the superoxide dismutase 1 protein. It is studied in amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (Antisense oligonucleotide)
Therapy area
Neurology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07883590 Phase 1 Amyotrophic Lateral Sclerosis Not yet recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral SclerosisCytochrome P-450 Enzyme System

More from ELI LILLY &

Follow LLY, the company behind LY3873862

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.